Zonagen (zona) - good buy? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Linda Kaplan who wrote (2391)	2/18/1998 3:43:00 PM
From: Dauntless	Read Replies (4) of 7041

Thanks Linda - Research report details I am waiting for a copy of the report but do have some details. Focus of report was Vivus. Contained basically one paragraph on Zonagen. 1- Dropout rate of 50% - that's great - I was hoping for efficacy of 40% which implies dropout rate of 60%. 2- Side effects & success related to dose. Vasomax HAS NO HIGH, MIDDLE AND LOW DOSE - doesn't make any sense. 3- No new clinical trials are planned as far as I know. I think they were just trying to round out their report on Vivus & failed to do their homework. More later - if I can get a copy. Maybe something will be said about this at the conference.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next